EFFECT ON ATRIAL NATRIURETIC PEPTIDES OF CHRONIC TREATMENT WITH ALPHA-METHYLDOPA AND HYDRALAZINE IN SPONTANEOUSLY HYPERTENSIVE RATS

被引：6

作者：

KOHNO, M

YASUNARI, K

MURAKAWA, K

YOKOKAWA, K

HORIO, T

KURIHARA, N

TAKEDA, T

机构：

[1] The First Department of Internal Medicine, Osaka City University Medical School, Asahi-machi, Abeno-ku

来源：

AMERICAN JOURNAL OF HYPERTENSION | 1990年 / 3卷 / 02期

关键词：

Atrial natriuretic peptides; Cardiac hypertrophy; Hydralazine; SHR; ±-methyldopa;

D O I：

10.1093/ajh/3.2.111

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

The present study was designed to examine the effect of antihypertensive therapy on plasma and atrial concentration of atrial natriuretic peptides (ANP) in spontaneously hypertensive rats (SHR) by using ±-methyldopa and hydralazine. Methyldopa and hydralazine treatment reduced blood pressure (P <. 05, P <. 05, respectively); however, ventricular weight was reduced by methyldopa (P <. 05) but not by hydralazine. Plasma ANP concentration in untreated SHR was higher than that observed in Wistar-Kyoto rats (WKY). Methyldopa treatment decreased plasma ANP concentration, but hydralazine treatment did not. Moreover, plasma ANP concentration and ventricular weight were positively correlated in untreated and treated SHR. The left atrial ANP concentration in untreated SHR was lower than that observed in WKY. Methyldopa treatment increased left atrial ANP concentration, but hydralazine treatment did not. These results suggest that the ANP release from the left atrium is chronically stimulated in adult SHR, and that a decrease in plasma ANP concentration by methyldopa treatment is, in part, associated with the decline of ANP release from the heart due to the reductions of blood pressure and cardiac hypertrophy. © 1990 by the American Journal of Hypertension, Ltd.

引用

页码：111 / 116

页数：6

共 36 条

[1]

De Bold A.J., Borenstein H.B., Veress A.T., Et al., A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats, Life Sci, 28, pp. 89-94, (1981)

[2]

Kangawa K., Matsuo H., Purification and complete amino acid sequence of a-human atrial natriuretic polypeptide (a-ANP), Biochem Biophys Res Commun, 118, pp. 131-139, (1984)

[3]

Atlas S.A., Kleinert H.D., Camargo M.J., Et al., Purification, sequencing and synthesis of natriuretic and vasoactive rat atrial peptide, Nature, 309, pp. 717-719, (1984)

[4]

Currie M.G., Geller M.D., Cole B.R., Et al., Purification and sequence analysis of bioactive atrial peptides (Atriopeptins), Science, 224, pp. 67-69, (1984)

[5]

Geller D.M., Currie M.G., Wakitani K., Et al., Atriopeptins: a family of potent biologically active peptides derived from mammalian atria, Biochem Biophys Res Commun, 20, pp. 333-338, (1984)

[6]

Kleinert H.D., Maack T., Atlas S.A., Et al., Atrial natriuretic factor inhibits angiotensin, norepipephrine, and potas-sium-induced vascular contractility, Hypertension, 6, pp. 143-147, (1984)

[7]

Yasujima M., Abe K., Kohzuki M., Et al., Atrial natriuretic factor inhibits the hypertension induced by chronic infu-sion of norepinephrine in conscious rats, Circulation, 57, pp. 470-474, (1985)

[8]

Atarashi K., Mulrow P., Franco-Saenz R., Et al., Inhibition of aldosterone production by an atrial extract, Science, 224, pp. 992-994, (1984)

[9]

Sugimoto T., Ishii M., Hirata Y., Et al., Increased release of atrial natriuretic polypeptides in rats with DOCA-salt hypertension, Life Sci, 38, pp. 1351-1358, (1986)

[10]

Imada T., Takayanagi R., Inagami T., Changes in the con-tent of atrial natriuretic factor with the progression of hypertension in spontaneously hypertensive rats, Biochem Biophys Res Commun, 133, pp. 759-765, (1985)

← 1 2 3 4 →